Peptides in Ageing: Sarcopenia, Frailty & Longevity
How endogenous peptide levels decline with age and what research suggests about peptide-based interventions for healthspan extension.
The Peptide Decline of Ageing
Ageing is accompanied by significant declines in multiple endogenous peptide hormones. Growth hormone secretion drops by approximately 14% per decade after age 30, a phenomenon called somatopause. By age 60, most adults produce less than half the GH they did at 25. GHK-Cu — a naturally occurring copper peptide involved in tissue repair — declines from ~200 ng/ml at age 20 to ~80 ng/ml by age 60. Thymic peptides decline as the thymus gland involutes, weakening adaptive immunity.
These declines are not merely biomarkers of ageing — they appear to be mechanistically involved in age-related deterioration. The question driving longevity peptide research is whether restoring these peptide levels to youthful ranges can slow or partially reverse aspects of biological ageing.
Sarcopenia: Muscle Loss with Ageing
Sarcopenia — the progressive loss of skeletal muscle mass and strength — affects approximately 10% of UK adults over 60 and up to 50% of those over 80. It is the primary driver of physical frailty, falls, and loss of independence. The NHS cost of sarcopenia-related fractures and care is estimated at billions annually.
Growth hormone and IGF-1 are essential for maintaining muscle protein synthesis. The age-related decline in GH/IGF-1 directly contributes to sarcopenia. GH secretagogues (CJC-1295, Ipamorelin, Sermorelin) are researched for their potential to counteract this decline, though evidence in elderly populations is limited and the risk-benefit profile differs from younger adults.
Myostatin inhibitors (Follistatin, ACE-031) represent another peptide approach — blocking the protein that actively limits muscle growth. Early clinical trials of myostatin-targeting therapies have shown modest muscle mass increases in elderly subjects, though functional improvements have been inconsistent.
Cellular Ageing: Telomeres & Mitochondria
Epitalon is the most studied peptide for telomere biology. This tetrapeptide (Ala-Glu-Asp-Gly) activates telomerase — the enzyme that extends telomere length. In preclinical studies, Epitalon treatment extended lifespan in animal models and improved various biomarkers of ageing. However, human longevity data is limited to observational studies from Russian research centres.
MOTS-c is a mitochondrial-derived peptide that improves mitochondrial function, glucose metabolism, and exercise capacity. It declines with age and is being studied as a potential exercise mimetic. MOTS-c treatment improved insulin sensitivity and physical performance in ageing animal models.
SS-31 (Elamipretide) targets the inner mitochondrial membrane, stabilising cardiolipin and improving electron transport chain efficiency. It has reached human clinical trials for mitochondrial myopathy and heart failure — conditions where mitochondrial dysfunction is central.
Immune Ageing (Immunosenescence)
The thymus — the organ responsible for T-cell maturation — begins involuting after puberty and is largely replaced by fatty tissue by age 50. This thymic involution is a major driver of age-related immune decline, increasing susceptibility to infections, reducing vaccine responses, and impairing cancer surveillance.
Thymic peptides (Thymosin Alpha-1, Thymalin) are researched for their potential to partially restore thymic function. Thymosin Alpha-1 is approved in several countries for hepatitis B and as an immune adjuvant. Thymalin has been studied in elderly populations in Russia with reported improvements in immune markers and reduced mortality over long follow-up periods — though these studies have methodological limitations by Western standards.
UK Context: Ageing Population
The UK's population is ageing rapidly — by 2030, one in four adults will be over 65. The NHS is already strained by age-related disease burden. Peptide research that could extend healthspan (years of healthy, independent living) rather than just lifespan has significant public health implications.
Currently, no peptide is NICE-approved specifically for healthy ageing. However, GLP-1 agonists' cardiovascular and metabolic benefits in older adults, teriparatide for osteoporosis, and growth hormone replacement for adult GH deficiency represent established peptide-based interventions that address age-related conditions within the NHS framework.
This article is for educational purposes only. Ageing is a complex biological process that no single intervention can reverse. Evidence-based approaches to healthy ageing include regular exercise, balanced nutrition, social engagement, and appropriate medical screening per NICE guidelines.